Abstract
Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Angiogenesis Inhibitors / adverse effects
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / blood supply
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Humans
-
Lung Neoplasms / blood supply
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Molecular Targeted Therapy
-
Protein Kinase Inhibitors / administration & dosage
-
Risk Assessment
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Protein Kinase Inhibitors
-
Bevacizumab